Helsinki University Central Hospital

Site:	Helsinki University Central Hospital	Go to their website
Address:
City:	Helsinki
State:
Zip:	FIN-00029
Country:	Finland

10 trials at this site

Phase	Trial	Trial Status	Site Status	Drug [asc]	NCT#
2	Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors	Completed	Closed	Dasatinib (BMS-354825)	NCT00568750
3	Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) (SSGXVIII/AIO)	Completed	Closed	Imatinib	NCT00116935
3	Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST	Active, not recruiting	Closed	Imatinib	NCT02413736
2	A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing c-Kit Gene (Extension of US Phase II study, B2222)	Completed	Closed	Imatinib	NCT00237185
2	A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST)	Active, not recruiting	Active	Imatinib + Regorafenib	NCT02365441
1	Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors	Active, not recruiting	Closed	Nivolumab + BMS-986016	NCT01968109
2	PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib	Completed	Closed	PTK787, ZK222584 (vatalanib)	NCT00117299
3	Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies (invictus)	Active, not recruiting	Closed	QINLOCK Ripretinib DCC-2618	NCT03353753
1	Radiation Therapy as Palliative Treatment of GIST (GIST-RT)	Completed	Closed	Radiation	NCT00515931
3	Study of Regorafenib as a 3rd-line or Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)	Ongoing, but not recruiting	Closed	Regorafenib (BAY 73-4506)	NCT01271712